At the recent 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden, Blood Cancer United’s Therapy Acceleration Program (TAP) company partners showcased strong clinical progress across blood cancers. TAP-supported companies presented advances spanning off-the-shelf cell therapies, targeted precision medicines, and next-generation immunotherapies, reinforcing TAP’s role in accelerating treatments with meaningful patient impact.
Off-the-Shelf Cell Therapies Expand Access & Improve Outcomes
TAP partners presented several “off-the-shelf” allogeneic cell therapies designed to overcome time and logistical barriers of patient-specific CAR-T manufacturing. These ready-made approaches could expand access to potentially curative therapies for patients with aggressive blood cancers.
Caribou Biosciences reported strong results for two allogeneic CAR-T programs during oral presentations. Vispa-cel achieved high responses including complete responses in relapsed large B-cell lymphoma with favorable safety, while CB-011 produced deep, durable responses and high MRD-negativity in relapsed multiple myeloma.
Wugen reported a trial in progress poster on WU-CART-007, an allogeneic CD7-targeted CAR-T for relapsed T-ALL/LBL. Earlier data showed high response and complete response rates in a setting with very limited curative options, supporting its FDA Breakthrough Therapy designation and ongoing pivotal trial development.
Together, these programs show how off-the-shelf cell therapies could broaden access, shorten time to treatment, and deliver durable responses in difficult-to-treat blood cancers.
Precision Therapies Target Genetic and Molecular Drivers
TAP partners also highlighted precision medicines that target key molecular drivers of leukemia, lymphoma, and myelofibrosis. These approaches are improving response depth, durability, and treatment options in areas where standard therapies remain limited.
Kura Oncology presented compelling data in frontline AML for ziftomenib, a menin inhibitor targeting NPM1-mutated and KMT2A-rearranged disease. High composite complete response rates and deep remissions show promise for a potential new AML backbone, building on ziftomenib’s recent approval as a monotherapy in relapsed NPM1-mutant AML.
Jazz Pharmaceuticals shared data for CPX-351 (Vyxeos®), originally developed by TAP partner Celator Pharmaceuticals, showing improved event-free survival as a bridge to transplant in high-risk MDS and oligoblastic AML. The results reinforce the continued value of this TAP-supported therapy beyond its original approved indication.
Novartis highlighted pelabresib, originally developed by TAP partner Constellation Pharmaceuticals, in myelofibrosis. Data showed benefits of pelabresib in combination with ruxolitinib across anemia, spleen reduction, and symptoms, supporting ongoing Phase 3 studies of this combination.
Ryvu Therapeutics reported encouraging activity for RVU120 in relapsed AML after venetoclax failure and early signals in myelofibrosis. The program’s CDK8/19 mechanism may help overcome venetoclax resistance while maintaining tolerability.
Secura Bio presented a trial in progress poster of the Phase 3 TERZO trial design for duvelisib, originally developed by TAP partner Verastem, in relapsed nodal T-cell lymphoma, building on prior Phase 2 activity in TFH-type disease and addressing a population with few effective targeted options.
Across these advances, TAP-supported precision therapies are moving from strong biological rationale to approvals, late-stage trials, and clearer patient benefit.
Next-Generation Immunotherapies Deliver Lasting Patient Benefits
TAP partners also presented next-generation immunotherapies designed to deliver deeper and more durable responses beyond conventional cell therapy or targeted drugs, along with favorable tolerability.
Faron Pharmaceuticals reported updated results from the BEXMAB study for bexmarilimab plus azacitidine in high-risk MDS, showing high response rates, durable complete remissions, and favorable tolerability in older patients. These results support the upcoming randomized BEXERA study.
BioInvent shared progress across two antibody programs. BI-1206, which may overcome rituximab resistance in B-cell lymphoma, showed strong response rates and manageable safety. BI-1808 showed durable activity in advanced CTCL by boosting anti-tumor immunity.
Dren Bio reported rapid, durable responses for DR-01 in large granular lymphocytic leukemia, a rare disease with no approved therapies. Responders experienced clinically meaningful recovery in blood counts, supporting expansion into related cytotoxic T- and NK-cell malignancies.
Enterome presented EO2463, an off-the-shelf peptide immunotherapy for indolent lymphoma that activates tumor-targeting T cells and may offer a low-toxicity early-intervention strategy to delay progression while preserving quality of life.
The data presented at EHA 2026 highlighted tangible patient impact across TAP’s portfolio: stronger responses, greater durability, more accessible treatment approaches, and continued momentum toward late-stage trials and approved therapies. Together, these updates demonstrate how donor-supported venture philanthropy is helping translate breakthrough blood cancer science into better outcomes for patients.